

University of Birmingham Research at Birmingham

Maximizing use of available population-based data on cardiometabolic diseases

Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)

DOI:

10.1016/S2213-8587(21)00328-4

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version
Peer reviewed version

Citation for published version (Harvard):

Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC) 2022, 'Maximizing use of available population-based data on cardiometabolic diseases', *The Lancet Diabetes and Endocrinology*. https://doi.org/10.1016/S2213-8587(21)00328-4

Link to publication on Research at Birmingham portal

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- •Users may freely distribute the URL that is used to identify this publication.
- •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- •User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 07. May. 2024

Maximizing Use of Available Population-Based Data on Cardiometabolic Diseases

1

25

2 David Flood¹⁻³, David Guwatudde⁴, Albertino Damasceno⁵⁻⁷, Jennifer Manne-Goehler^{8,9*}, Justine 3 4 I. Davies^{10-12*}, for the Global Health & Population Project on Access to Care for Cardiometabolic 5 Diseases (HPACC)† 6 7 ¹Division of Hospital Medicine, Department of Medicine, University of Michigan, Ann Arbor, 8 Michigan, USA; ²Center for Indigenous Health Research, Wuqu' Kawoq, Tecpán, Guatemala; 9 ³Research Center for the Prevention of Chronic Diseases, Institute of Nutrition of Central 10 America and Panama, Guatemala City, Guatemala; ⁴Department of Epidemiology and 11 Biostatistics, School of Public Health, Makerere University, Kampala, Uganda; ⁵Department of 12 Public and Forensic Health Sciences and Medical Education, Faculty of Medicine, University of 13 Porto, Porto, Portugal; ⁶EPIUnit, Institute of Public Health, University of Porto, Porto, Portugal; 14 ⁷Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique; ⁸Division of 15 Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 16 USA; 9Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical 17 School, Boston, MA, USA; ¹⁰Institute for Applied Health Research, University of Birmingham, 18 UK; 11 Centre for Global Surgery, Department of Global Health, Stellenbosch University, Cape 19 Town, South Africa; ¹²Medical Research Council/Wits University Rural Public Health and Health 20 Transitions Research Unit, Faculty of Health Sciences, School of Public Health, University of the 21 Witwatersrand, Johannesburg, South Africa 22 23 *Joint senior authors 24 †Members listed at end of paper

- 26 Corresponding author:
- 27 Justine I. Davies, MD
- 28 Institute for of Applied Health Research
- 29 University of Birmingham
- 30 Birmingham, United Kingdom
- 31 B15 2TT
- 32 <u>J.davies.6@bham.ac.uk</u>

33

- 34 Word count: <u>907</u>947
- 35 References: 10

The absolute worldwide burden of adult cardiometabolic diseases such as hypertension, diabetes, obesity, and dyslipidemia continues its relentless ascent. Scaling up the prevention, management, and control of cardiometabolic diseases is cost-effective but requires strong health systems. 14 Building thesestrong health systems requires data that are accurate, timely, and transparent, as we have previously argued in this journal.² In particular, data from highquality population-based surveys are critical, as they reflect the spectrum of community-dwelling adults in a particular geography, including those who are not reached by the health system. There Of late, there has been tremendous progress in making population-based survey data available for cardiometabolic diseases. Emblematic of this has been the release in 2018 of the World Health Organization (WHO) Noncommunicable Disease (NCD) Microdata Repository.³ This hosts over 130 surveys conducted using the STEPwise approach to NCD surveillance (STEPS) methodology that are now available after to users who submit a brief application. Most STEPS surveys are conducted in low- and middle-income countries (LMICs) where a majority of the cardiometabolic disease burden occurs. Thus, this resource fills a critical gap in openly accessible population-based survey data on cardiometabolic risk factors and health care access in these settings. Yet, there is more work to be done. The availability of population-based data, while necessary, is insufficient by itself to ensure their effective use to shape programs, strategies, and policies addressing cardiometabolic diseases. In this Comment, we highlight three other crucial actions needed to maximize the use of population data: harmonization, alignment with monitoring indicators to benchmark health system performance, and capacity-building initiatives to democratize data use (figure).

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Our perspective is informed by our experience in the Global Health and Population Project on Access to Care for Cardiometabolic diseases (HPACC), an international research consortium with collaborators in more than 30 countries, . HPACC has created a dynamic repository of harmonized, nationally representative survey data currently representing 1.3 million individuals in more than 75 LMICs (including more than 50 STEPS surveys).) to address questions of relevance to health system planning and evaluation for cardiometabolic diseases.

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

61

62

63

64

65

66

First, while population-based data-can and should be used at the national level, these data also should be harmonized to maximize its use by international advocacy organizations, policymakers, and researchers. Harmonization refers to the process of bringing together distinct data sources into a single comparable format. Harmonized survey data are available in the area of maternal and child health, 4 but no such resource exists for cardiometabolic diseases. Such harmonized data allows for assessing health system effectiveness and responsiveness, as our study of the state of hypertension care in 44 LMICs illustrates.⁵⁵ Harmonization-also provides larger and more diverse samples, giving added power to study variations in cardiometabolic risk factors, including biological measures such as blood glucose and behavioral risk factors such as physical activity and diet. Understanding these variations is important, as it cannot be assumed that epidemiologic patterns of clinical relevance observed in well-studied high-income countries will be conserved in LMICs. Indeed, we have found that the association between diabetes and body mass index (BMI) is highly variable across world regions, implying that BMI thresholds generated using European or North American data cannot simply be applied elsewherein other world regions. 6 Harmonization also allows for the construction of sophisticated clinical and policy models for the prevention, treatment, and control of cardiometabolic diseases to predict effects of change. 1,76 Importantly, to ensure that data are useful for cross-country comparisons, prior to data collection, time should be spent ensuring survey instruments and data collection are standardized and aligned with the highest priority global health metrics.

Second, population data on cardiometabolic diseases should be harnessed to benchmark and monitor health system performance. At present, these data are underutilized for this purpose. Harmonized data from STEPS and similarnon-STEPS surveys can reveal progress on monitoring indicators in the NCD Global Monitoring Framework⁷ and inform new targets such as those proposed by the WHO Global Diabetes Compact, a recently established initiative to improve global diabetes care. To show global variation in health system performance, harmonized data ideally should include not only LMICs but also high-income countries, though unfortunately data from high-income countries are currently less available.

Third, given limited research capacity in many LMICs, there is a need to build capacity to ensure the wide usability of population data on cardiometabolic diseases, most especially by those who have collected it. Local researchers—especially those in LMICs—who design and conduct surveys should be empowered to use harmonized data to answer their policy-relevant questions, conduct independent analyses, and publish in lead-author roles. In addition to this being a step towards decolonialization of global health, these collaborators add critical contextual interpretation that may not be fully perceived or appreciated by those outside their settings.

maximizing use of available population data on cardiometabolic diseases, it is important to continue data-sharing efforts. Many STEPS and comparable non-STEPS household surveys remain unavailable, as are more than two dozen nationally representative health facility surveys conducted using the WHO Service Availability Readiness Assessment (SARA) methodology. Additionally, many other data sources, for example, from subnational research studies, remain inaccessible. Finally, cardiometabolic disease epidemiology is rapidly evolving, but data are often historical. As is done for HIV, data collection for cardiometabolic diseases needs to be ongoing to assess temporal trends in disease prevalence and health system performance.

While we focus on maximizing use of available population data on cardiometabolic diseases, it is important to continue data-sharing efforts. Many STEPS and comparable non-STEPS household surveys remain unavailable, as are more than two dozen nationally representative health facility surveys conducted using the WHO Service Availability Readiness Assessment (SARA) methodology. Additionally, many other data sources, for example, from subnational research studies, remain inaccessible. Finally, cardiometabolic disease epidemiology is rapidly evolving, but data are often historical. As is done for HIV, data collection for cardiometabolic diseases needs to be ongoing to assess temporal trends in disease prevalence and health system performance.

The staggering burden of cardiometabolic diseases brings with it an imperative to maximize the use of these data. Many countries and individuals LMICs already have invested substantial resources in producing these data, which are a global public good. However, while they are increasingly available, in practice they these data are still too sparse and underutilized given the toll these diseases are taking on people worldwide. We call on funders and international health organizations to invest in efforts to collect, harmonize and make available these data with an urgency befitting the magnitude of the global burden of cardiometabolic diseases.

131	<u>Declaration of interests</u>
132	DF reports grant funding within the 3 years from a Pilot and Feasibility Grant funded by the
133	Michigan Center for Diabetes Translational Research (NIH Grant P30-DK092926) and a grant
134	from the Swinmurn Foundation to implement a sustainable diabetes clinic in Guatemala. DF
135	also reports volunteer affiliations with Wuqu' Kawoq and GlucoSalud, outside the submitted
136	work. During the course of this work, DF has received research fellowship funding from National
137	Clinician Scholars Program at the University of Michigan Institute for Healthcare Policy &
138	Innovation. TB reports grants from the Alexander von Humboldt Foundation, Wellcome Trust,
139	and U.S. National Institutes of Health. RA reports contracts with Novo Nordisk, Union for
140	International Cancer Control's (UICC), Novo Nordisk, Hoffman-La Roche, and Sloan Memorial
141	Kettering Hospital, outside the submitted work. RA also reports payments or honorario from
142	Merck and Hoffmann-La Roche, outside the submitted work. All other authors declare no
143	competing interests.
144 145	
146	References
147	1. Basu S, Flood D, Geldsetzer P, et al. Estimated impact of increased diagnosis,
148	treatment, and control of diabetes mellitus among low-and middle-income countries: A
149	microsimulation model. Lancet Global Health 2021; (Accepted; in press).
150	2. Davies J, Yudkin JS, Atun R. Liberating data: the crucial weapon in the fight against
151	NCDs. Lancet Diabetes Endocrinol 2016; 4(3): 197-8.

152 3. World Health Organization. NCD Microdata Repository. 2021.

153 https://extranet.who.int/ncdsmicrodata/index.php/catalog (accessed July 19, 2021).

IPUMS. IPUMS Global Health. 2021. https://globalhealth.ipums.org/ (accessed October
 25, 2021).

- 156 5. Geldsetzer P, Manne-Goehler J, Marcus ME, et al. The state of hypertension care in 44
- 157 low-income and middle-income countries: a cross-sectional study of nationally representative
- individual-level data from 1.1 million adults. *Lancet* 2019; 394(10199): 652-62.
- 159 6. Teufel F, Seiglie JA, Geldsetzer P, et al. Body-mass index and diabetes risk in 57 low-
- income and middle-income countries: a cross-sectional study of nationally representative,
- individual-level data in 685 616 adults. *Lancet* 2021; 398(10296): 238-48.
- 162 7. WHO. Noncommunicable Diseases Global Monitoring Framework: Indicator Definitions
- and Specifications. 2014. https://www.who.int/nmh/ncd-
- 164 tools/indicators/GMF Indicator Definitions Version NOV2014.pdf (accessed September 29,
- 165 2021).
- 166 8. Hunt D, Hemmingsen B, Matzke A, et al. The WHO Global Diabetes Compact: a new
- initiative to support people living with diabetes. Lancet Diabetes Endocrinol 2021; 9(6): 325-7.
- 168 9. Wang W, Assaf S, Pullum T, Kishor S. The Demographic and Health Surveys Faculty
- 169 Fellows Program: Successes, Challenges, and Lessons Learned. Glob Health Sci Pract 2021;
- 170 9(2): 390-8.
- 171 10. Mangipudi S, Leather A, Seedat A, Davies J. Oxygen availability in sub-Saharan African
- 172 countries: a call for data to inform service delivery. The Lancet Global Health 2020; 8(9): e1123-
- 173 e4.

HPACC members

176

188 189

190

191 192

193

194

195

196

197

198

199 200

201

202

203

204

205

206

207208

209

210

211212

213

214

215

216

217218

219

220

221222

223

224

225226

177 David Flood¹⁻³, David Guwatudde⁴, Albertino Damasceno⁵⁻⁷, Krishna K. Aryal⁸, Rifat Atun^{9,10}, Till 178 W. Bärnighausen¹¹⁻¹³, Brice Wilfried Bicaba¹⁴, Pascal Bovet^{15,16}, Gary Brian¹⁷, Maria 179 Dorobantu¹⁸, Farshad Farzadfar¹⁹, Gladwell Gathecha²⁰, Pascal Geldsetzer^{11,21}, Mongal Singh 180 Gurung²², Corine Houehanou²³, Nahla Hwalla²⁴, Lindsay Jaacks²⁵, Jutta Jorgensen²⁶, Gibson Kagaruki²⁷, Khem Karki²⁸, Demetre Labadarios²⁹, Nuno Lunet^{5,30}, Maja E. Marcus³¹, Joao 181 182 Martins³², Mary Mayige²⁷, Omar Mwalim^{33,34}, Kibachio Joseph Mwangi^{20,35}, Bolormaa Norov³⁶, 183 Rebekka Rühle³¹, Sahar Saeedi Moghaddam³⁷, Jacqueline A. Seiglie³⁸, Abla M. Sibai³⁹, Bahendeka Karaireho Silver⁴⁰, Andrew Stokes⁴¹, Lela Sturua⁴², Adil Supiyev⁴³, Michaela 184 185 Theilmann¹¹, Lindiwe Tsabedze⁴⁴, Sebastian Vollmer³¹, Kehinde D. Whyte-Ilori⁴⁵, Zhaxybay Zhumadilov⁴⁶, Jennifer Manne-Goehler^{47,48}, Justine I. Davies⁴⁹⁻⁵¹ 186 187

Affiliations

¹Division of Hospital Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA; ²Center for Indigenous Health Research, Wuqu' Kawoq, Tecpán, Guatemala; ³Research Center for the Prevention of Chronic Diseases, Institute of Nutrition of Central America and Panama, Guatemala City, Guatemala; ⁴Department of Epidemiology and Biostatistics, School of Public Health, Makerere University, Kampala, Uganda; 5Department of Public and Forensic Health Sciences and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal; ⁶EPIUnit, Institute of Public Health, University of Porto, Porto, Portugal; ⁷Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique; ⁸Monitoring Evaluation and Operational Research Project, Abt Associates, Kathmandu, Nepal; 9Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA; ¹⁰Department of Global Health and Social Medicine, Harvard Medical School, Harvard University, Boston, MA, USA; ¹¹Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany; ¹²Africa Health Research Institute, Somkhele, South Africa; ¹³Harvard Center for Population and Development Studies, Cambridge, USA; ¹⁴Institut National de Santé Publique, Burkina Faso; ¹⁵Ministry of Health, Victoria, Sevchelles: ¹⁶Institute of Social and Preventive Medicine, Lausanne, Switzerland; ¹⁷The Fred Hollows Foundation New Zealand; ¹⁸University of Medicine and Pharmacy Carol Davila, Bucharest. Romania; ¹⁹Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; ²⁰Division of Non-Communicable Diseases, Ministry of Health, Nairobi, Kenya; ²¹Division of Primary Care and Population Health, Stanford University; ²²Health Research and Epidemiology Unit, Ministry of Health, Thimphu, Bhutan; ²³Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin; ²⁴Faculty of Agricultural and Food Sciences, American University of Beirut, Beirut, Lebanon; ²⁵Global Academy of Agriculture and Food Security, The University of Edinburgh, Midlothian, United Kindom; ²⁶Department of Public Health, University of Copenhagen, Copenhagen, Denmark; ²⁷National Institute for Medical Research, Dar es Salaam, Tanzania; ²⁸Department of Community Medicine and Public Health, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal; ²⁹Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa; ³⁰EPIUnit Institute of Public Health, University of Porto, Porto, Portugal; ³¹Department of Economics and Centre for Modern Indian Studies, University of Göttingen, Göttingen, Germany; ³²Faculty of Medicine and Health Sciences, National University of East Timor, Dili, Timor-Leste; ³³Ministry of Health and Social Welfare, Elderly, Gender and Children, Zanzibar, Tanzania; ³⁴Bergen Centre for Ethics and Priority Setting (BCEPS), Department of Global Public Health and Primary Care, University of Bergen, Norway; ³⁵Faculté de Médecine, Université de Genève, Geneva, Switzerland; ³⁶National Center for Public Health, Ulaanbaatar, Mongolia;

227 ³⁷Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical 228 Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; ³⁸Diabetes Unit, Massachusetts General Hospital, Boston, United States of America; ³⁹Epidemiology and 229 Population Health Department. Faculty of Health Sciences American University of Beirut. Beirut. 230 Lebanon; ⁴⁰Uganda Martyrs University | Saint Francis Hospital Nsambya, Kampala, Uganda; 231 ⁴¹Department of Global Health, Boston University School of Public Health, Boston, United 232 States of America; ⁴²Non-Communicable Disease Department, National Center for Disease 233 234 Control and Public Health, Tbilisi, Georgia; ⁴³Laboratory of Epidemiology and Public Health, 235 Center for Life Sciences, Nazarbayev University, Astana, Kazakhstan; ⁴⁴Ministry of Health, Mbabane, Eswatini; ⁴⁵School of Medicine, University of Leeds, Leeds, West Yorkshire, United 236 Kingdom; ⁴⁶Nazarbayev University School of Medicine, Nur-Sultan, Kazakhstan; ⁴⁷Division of 237 Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 238 239 USA; ⁴⁸Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; ⁴⁹Institute for Applied Health Research, University of Birmingham, 240 UK; 50 Centre for Global Surgery, Department of Global Health, Stellenbosch University, Cape 241 242 Town, South Africa; 51 Medical Research Council/Wits University Rural Public Health and Health 243 Transitions Research Unit, Faculty of Health Sciences, School of Public Health, University of the 244 Witwatersrand, Johannesburg, South Africa;" 245